From the Journals

AI-assisted colonoscopy doesn’t always improve adenoma detection: Study


 

FROM THE AMERICAN JOURNAL OF GASTROENTEROLOGY

Additional considerations

In a separate evaluation of EndoVigilant, the frame level sensitivity was 0.9 and the frame level specificity was 0.97. These calculations were conducted on a dataset not used in training or validation of this model, the authors noted.

In this study, it’s possible that experienced community-based endoscopists are proficient at detecting the adenomas highlighted by the CADe system, so the technology may not detect a significant number of additional adenomas, the authors wrote. It’s also possible that some endoscopists ignore lesions highlighted by CADe, including small lesions that might be difficult to identify as adenomas or are seen as clinically unimportant, which could reduce the potential benefit of CADe.

“It’s important to remember that these tools are meant to be endoscopist assistance devices, not endoscopist replacements. They provide added benefit by pointing out polyps while we do the best exam we can,” Aasma Shaukat, MD, a professor of medicine and gastroenterologist at NYU Langone Health, New York, said in an interview.

Dr. Shaukat, who wasn’t involved with this study, has researched CADe for screening and surveillance colonoscopies. She and colleagues found that CADe use improved APC without an increase in resection of nonneoplastic lesions.

“Different trials have reported different results, and at the end of the day, it’s an endoscopist assistance tool, like spellcheck in a document,” she said. “It’s nice if spellcheck points to an incorrect spelling, but you don’t have to use it. Similarly, we often don’t know in these studies what an endoscopist felt or believed about the tool when using it.”

The benefits of CADe could vary based on its software, setting, number of patients, patient characteristics, number of clinicians, provider experience and training, dual- versus single-monitor setup, and even time of day, she noted. Future studies could clarify these factors, as well as improve the technology.

“This is just the beginning of AI in this field, and while bounding boxes to indicate potential polyps is a good start, it’s not the be-all, end-all,” Dr. Shaukat said.

“We want AI software to be able to tell us more about the size of the polyp, histology, prep quality, landmarks in the colon, adequacy of resection, and more. There’s some work being geared toward developing the algorithms to do these additional aspects,” she added.

The study was sponsored by EndoVigilant. Some of the authors reported consultant roles with Neptune Medical, AgilTx, Intuitive Surgical, Capsovision, and EndoVigilant. Dr. Shaukat reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Do biologics protect against cancer progression in IBD?
MDedge Hematology and Oncology
A patient named ‘Settle’ decides to sue instead
MDedge Hematology and Oncology
Does appendectomy raise the risk for colorectal cancer?
MDedge Hematology and Oncology
Canadian guidance recommends reducing alcohol consumption
MDedge Hematology and Oncology
New cancer data spark outcry from patient advocates
MDedge Hematology and Oncology
Room for improvement in Barrett esophagus care
MDedge Hematology and Oncology
The 5-year survival rate for pancreatic cancer is increasing
MDedge Hematology and Oncology
Strategy to reduce peritoneal metastases in gastric cancer
MDedge Hematology and Oncology
Colorectal cancer incidence doubled in younger adults
MDedge Hematology and Oncology
Does CRC risk in IBD extend to close family members?
MDedge Hematology and Oncology